Liquidia Corporation (LQDA) 2026 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to Liquidia Corporation first-quarter 2026 financial results and corporate update conference call. My name is Jonathan, and I will be your operator today. (Operator Instructions) Please note that today's call is being recorded.

    早安,歡迎參加 Liquidia Corporation 2026 年第一季財務業績與公司最新進展電話會議。我叫 Jonathan,今天將擔任會議接線員。(接線員指示) 請注意,今天的電話會議將被錄音。

  • And now I'd like to turn the call over to Jason Adair, Liquidia's Chief Business Officer. You may proceed.

    現在我想把電話交給 Liquidia 首席商務長 Jason Adair。請開始。

  • Jason Adair - Chief Business Officer

    Jason Adair - Chief Business Officer

  • Thank you, and good morning, everyone. It's my pleasure to welcome you to our first-quarter 2026 financial results and corporate update call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Schundler, our General Counsel.

    謝謝,各位早安。很高興歡迎各位參加我們 2026 年第一季財務業績與公司最新進展電話會議。今天與我一同出席的有:執行長 Roger Jeffs 博士;營運長兼財務長 Michael Kaseta;醫務長 Rajeev Saggar 博士;商務長 Scott Moomaw;以及總法律顧問 Rusty Schundler。

  • Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may cause actual results to differ materially. For further information, please refer to our filings with the SEC, which are available on our website. Please also note that our earnings release and our commentary include non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures can be found in our earnings press release.

    在開始之前,請注意今天的討論將包含前瞻性陳述,包括關於未來業績、產品表現以及持續中的臨床或商業活動之陳述。這些陳述受到風險與不確定性影響,可能導致實際結果出現重大差異。欲了解更多資訊,請參閱我們向美國證券交易委員會(SEC)提交的文件,相關文件可於我們網站取得。另請注意,我們的財報新聞稿與管理層評論包含非 GAAP 財務衡量指標。這些非 GAAP 財務衡量指標與最可比 GAAP 指標之調節表,可在我們的財報新聞稿中找到。

  • With that, I'll turn the call over to Roger.

    接下來,我把電話交給 Roger。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Thanks, Jason, and good morning, everyone. We're delighted to share our business results with you today. We'll keep our prepared remarks somewhat brief this morning as we'd like to allow as much time for questions as we can. Having said that, I'd like to share some bigger picture thoughts regarding the state of the business and allow the Q&A to serve as the time to delve into the specifics.

    謝謝你,Jason,各位早安。我們很高興今天與各位分享我們的營運成果。今天早上的準備講稿我們會盡量簡短,因為希望能留出更多時間回答問題。話雖如此,我想先分享一些關於公司整體營運狀況的宏觀觀點,並把具體細節留到問答時間再深入討論。

  • Three full quarters into the commercial launch of YUTREPIA, I would summarize the state of our business with three main points. The first is that in the third full quarter on the market, YUTREPIA now leading the growth of the inhaled prostacyclin category. YUTREPIA is well on its way to becoming the anchored inhaled therapy for patients with PAH and PH-ILD. As of April 30, we have received approximately 4,500 unique patient prescriptions and started approximately 3,750 patients on therapy since launch. And approximately 980 physicians have prescribed YUTREPIA since launch. This breadth of prescription is also complemented by increasing depth of prescriptions.

    在 YUTREPIA 商業化上市後的第三個完整季度,我會用三個重點來總結我們的業務現況。第一,在上市後第三個完整季度,YUTREPIA 現在正引領吸入型前列環素(prostacyclin)類別的成長。YUTREPIA 正穩步成為 PAH 與 PH-ILD 患者的核心吸入治療選項。截至 4 月 30 日,自上市以來我們已收到約 4,500 份不重複患者處方,並已讓約 3,750 名患者開始接受治療。此外,自上市以來約有 980 位醫師開立過 YUTREPIA 處方。處方的廣度提升,同時也伴隨處方深度的增加。

  • For example, just since the end of February, the number of physicians who have prescribed YUTREPIA to 5 or more patients has grown 25% to approximately 270 physicians. What this clearly demonstrates is that physicians who try YUTREPIA are coming back to it for more and more of their patients. That is the pattern you see when a therapy is becoming foundational to a treatment paradigm, not when it is being trialed as an alternative and strongly suggests that YUTREPIA is already establishing itself as the best-in-class and first in choice inhaled therapy.

    例如,自 2 月底以來,為 5 名或以上患者開立過 YUTREPIA 的醫師人數增加了 25%,達到約 270 位。這清楚顯示,嘗試使用 YUTREPIA 的醫師會再次回到這個療法,並用於越來越多的患者。當一項療法正成為治療模式中的基礎用藥時,就會出現這樣的趨勢;而不是僅被當作替代方案試用。這也強烈暗示 YUTREPIA 已在建立其同類最佳(best-in-class)且為首選的吸入治療地位。

  • This increasing breadth and depth of prescriptions is driven by a product profile that is setting a new bar for others to match, one where targeted pulmonary delivery minimizes off-target effects with the formulation technology that preferentially lessens upper airway intolerance while enhancing local effects on the alveolar capillary membrane. This allows for higher dose attainment and most importantly, better and more durable patient outcomes.

    處方廣度與深度的提升,源自於其產品特性正在樹立新的標竿:以目標性肺部遞送降低非目標部位的不良影響,並透過配方技術優先減輕上呼吸道不耐受,同時增強對肺泡—毛細血管膜的局部作用。這使得患者能達到更高劑量;更重要的是,帶來更佳且更持久的患者治療結果。

  • The second main point is that we are purposefully and diligently broadening the opportunity in front of us by launching additional studies. We have started recruiting into Cohort B of the ASCENT study. to transition inadequate responders from Tyvaso DPI to YUTREPIA. And in order to provide empiric evidence that higher doses of YUTREPIA are uniquely well tolerated and advantage versus competitive alternatives.

    第二個重點是,我們正有目的且嚴謹地透過啟動更多研究,擴大眼前的機會版圖。我們已開始在 ASCENT 研究的 B 組(Cohort B)招募,將對 Tyvaso DPI 反應不足的患者轉換至 YUTREPIA。同時,我們也希望提供實證證據,證明較高劑量的 YUTREPIA 具有獨特的良好耐受性,並相較競品替代方案具備優勢。

  • Additionally, we are actively screening patients in our pivotal Phase 3 RESPIRE study of L606, the most tolerable inhaled treprostinil study to date as advanced by our 48-week data from the open-label US study in PAH and PH-ILD patients. In addition, we are also advancing clinical programs to expand the role of inhaled prostacyclin into other serious pulmonary and vascular diseases. such as IPF, PPF, PH-COPD and Scleroderma-associated Raynaud's phenomenon. For all of these opportunities, mechanistic validation largely exist, the unmet need and high opportunity value remain.

    此外,我們正在關鍵性第 3 期 RESPIRE 研究中積極篩選患者;該研究評估 L606,這是迄今耐受性最佳的吸入型 treprostinil 研究,並已由我們在 PAH 與 PH-ILD 患者之美國開放標籤研究 48 週數據所支持。另外,我們也在推進臨床計畫,將吸入型前列環素的角色擴展至其他嚴重的肺部與血管疾病,例如 IPF、PPF、PH-COPD,以及硬皮症相關雷諾氏現象。對於上述所有機會,其作用機轉的驗證大多已存在,而未被滿足的醫療需求與高機會價值仍然明確。

  • We believe the differentiated tolerability and dosing profiles of both YUTREPIA and L606 is foundational to that opportunity. as it may support improved patient retention while also enabling higher therapeutic exposures over time. The through line of our clinical investment is that we have extraordinary and real potential to expand the franchise value of our portfolio by multiples in the years to come, with therapies that reimagine what a best-in-class profile must be.

    我們相信,YUTREPIA 與 L606 具差異化的耐受性與劑量特性,是上述機會的基礎;因為這可能有助於提升患者留存率,同時也能讓患者隨時間達到更高的治療暴露。我們臨床投資的一貫主軸是:未來數年,我們具備非常顯著且真實的潛力,透過重新定義同類最佳產品應具備的特性,使產品組合的特許經營價值(franchise value)成倍擴大。

  • The third main point is that we have established a profitable self-funded business in a remarkably short period of time. We have now delivered our third consecutive quarter of profitability with top line growing, bottom line growing and cash growing which Mike will expand on shortly. What that gives us is the freedom to reinvest our own profits into the next phase of the company's growth.

    第三個重點是,我們在極短時間內建立了一個可獲利、可自我資助的業務。我們已連續第三個季度實現獲利,營收成長、獲利成長、現金也成長;Mike 稍後會進一步說明。這讓我們能夠自由地把自身獲利再投資到公司下一階段的成長。

  • We are building new manufacturing capacity. We're advancing both YUTREPIA and L606 in a related array of clinical studies, and we are doing it all of it from operating cash flow rather than via the capital markets. This is rare in our business, especially at this early stage of our commercial life cycle.

    我們正在建置新的製造產能。我們正推進 YUTREPIA 與 L606 在一系列相關臨床研究中的進展,而且這一切都以營運現金流支應,而非透過資本市場籌資。在我們這個產業中,尤其在商業化生命週期如此早期的階段,這是相當罕見的。

  • To put it all in context, we could not be happier with where the business is today, and we are even more excited about where it is going. YUTREPIA has already exceeded $0.5 billion in annualized net revenue run rate in less than one full year on the market. Our clinical programs are fully funded by operating cash flow and we have a clear line of sight to at least $1 billion in net revenue in 2027 with multiple growth opportunities to sustain further growth well into the future. And what gives us confidence in achieving our ambitions is that the engine that gets us there is already up and running flawlessly.

    綜合來看,我們對公司目前的狀況感到非常滿意,也對未來走向更加振奮。YUTREPIA 在上市未滿一年內,年化淨營收執行率(run rate)已超過 5 億美元。我們的臨床計畫完全由營運現金流支應,且我們清楚可見在 2027 年至少達到 10 億美元淨營收的路徑,並有多項成長機會可在未來持續推動更進一步的成長。而讓我們有信心實現目標的是:帶領我們達成這些成果的引擎,已經啟動並且運作得非常順暢。

  • With that, I'll turn it over to Mike to walk you through the financials.

    接下來,我把電話交給 Mike,請他帶各位回顧財務表現。

  • Michael Kaseta - Chief Financial Officer and Chief Operating Officer

    Michael Kaseta - Chief Financial Officer and Chief Operating Officer

  • Thank you, Roger, and good morning, everyone. As Roger has indicated, the first quarter is a continuation of the story that we discussed in March, sustained patient growth and disciplined execution. Net product sales of YUTREPIA were $129.9 million in the first quarter of 2026, up from $90.1 million in the fourth quarter of 2025, representing 44% sequential growth in net product sales. The first quarter also marked our third consecutive quarter of increasing profitability and the growth from quarter-to-quarter is striking.

    謝謝你,Roger,各位早安。如 Roger 所指出,第一季延續了我們在 3 月所討論的故事:患者人數持續成長,以及有紀律的執行。2026 年第一季 YUTREPIA 產品淨銷售額為 1.299 億美元,高於 2025 年第四季的 9,010 萬美元,淨銷售額季增 44%。第一季也標誌著我們連續第三個季度獲利能力提升,而且季度間的成長幅度相當顯著。

  • Net income was approximately $52.9 million, up from $14.6 million in the fourth quarter of 2025. Non-GAAP adjusted EBITDA was approximately $71.2 million, up from $27.3 million. We almost tripled our EBITDA profitability from Q4 to Q1.

    淨利約為 5,290 萬美元,較 2025 年第四季的 1,460 萬美元增加。非 GAAP 調整後 EBITDA 約為 7,120 萬美元,較 2,730 萬美元增加。我們從第四季到第一季的 EBITDA 獲利能力幾乎成長了三倍。

  • We've achieved this increase in profitability while continuing to invest more heavily into the commercial organization through our sales force expansion and expanding our manufacturing capacity and footprint in North Carolina and in our clinical development programs. We ended the quarter with approximately $222.8 million in cash and cash equivalents, an increase of $32.1 million from year-end. So in addition to growing the top line, we continue to grow the balance sheet that funds our priorities and are confident in our ability to remain profitable in the future.

    我們在達成這項獲利能力提升的同時,仍持續加大對商業組織的投資,包括擴編銷售團隊、擴大我們在北卡羅來納州的製造產能與據點,以及推進臨床開發計畫。本季末我們持有約 2.228 億美元的現金及約當現金,較年末增加 3,210 萬美元。因此,除了營收成長之外,我們也持續強化用以支應優先事項的資產負債表,並對未來維持獲利的能力充滿信心。

  • Roger, back to you.

    Roger,交回給你。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Thanks, Mike. As we close out our third quarter on the market, what stands out to me is how much we have built in such a short period of time, a product that is leading the growth of the inhaled prostacyclin category in PAH and PH-ILD. a pipeline with multiple paths to extend the franchise well beyond where it stands today and a self-funded business with the freedom to invest in its own future. We have never been more confident in where this company is headed based on the robust momentum we continue to see in this business.

    謝謝你,Mike。當我們結束上市後的第三個季度時,最令我印象深刻的是,我們在如此短的時間內建立了這麼多成果:一項在 PAH 與 PH-ILD 的吸入式前列環素(prostacyclin)類別中引領成長的產品;一條具備多條路徑、可將產品線延伸至遠超過目前定位的研發管線;以及一個可自我資助、能自由投資自身未來的事業。基於我們在業務上持續看到的強勁動能,我們對公司未來走向的信心前所未有地高。

  • With that, operator, please open the line for questions.

    接下來,接線員,請開放提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Amy Li, Jefferies.

    Jefferies 的 Amy Li。

  • Amy Li - Equity Analyst

    Amy Li - Equity Analyst

  • Excellent. Congrats on the amazing progress and thanks so much for taking our question. Based on our math, it looks like you're seeing a slight acceleration of unique scripts and patient ads as well as an improvement in script to start in March and April. Can you give us a sense of what current growth is being driven by in terms of PAH versus PH-ILD, new patients or switches academic or community and any other relevant metrics. And then just a quick follow-up. Do you see any read across from the Hikma versus Amarin Supreme Court case to the 327 litigation? Thanks so much.

    太好了。恭喜取得令人驚豔的進展,也非常感謝回答我們的問題。依我們的計算,看起來你們在 3 月與 4 月的獨立處方數(unique scripts)與新增病患(patient adds)略有加速,同時處方到啟用(script to start)也有所改善。能否請你們說明目前成長主要由哪些因素驅動:例如 PAH 相較於 PH-ILD 的貢獻、新病患或轉換用藥、學術中心或社區端,以及其他相關指標。接著一個簡短追問。你們是否認為 Hikma 對 Amarin 的最高法院案件,對 327 訴訟有任何可供參照之處?非常感謝。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Good morning, Amy. Thanks for the question. So there has been a slight acceleration in referrals and patient starts. But I'd say largely things are sustained and consistent. We don't want to forecast accelerating growth here. I think if we sustain the growth that we've seen since the beginning of launch and you just take that at your average, I think everything we've predicted around 2027 being $1 billion in net revenues, still holds true for us.

    早安,Amy。謝謝你的提問。確實,轉介與病患啟用(starts)有些微加速。但我會說整體而言大致維持且相當一致。我們不希望在此對加速成長做出預測。我認為,只要我們維持自上市以來所見的成長,並以其平均水準來看,我們先前對 2027 年淨營收達 10 億美元的預期,對我們而言仍然成立。

  • I think where we're seeing robust growth is, as we sort of highlighted in the script is that is in the depth of prescriptions. So we are gaining more prescribers, and we're just getting them to trial the drug. And certainly, as they get to two, three, four and five starts, then you start to see sort of this almost trigger change where they just begin using YUTREPIA preferentially. And I think the product profile is speaking for itself, that is redefining kind of what is required for prostacyclin therapy. You need one that's direct to the site of injury. So it has to be to the lung. It has to minimize lung intolerance as well as off-target effects, which the print formulation certainly does.

    我認為我們看到的強勁成長,正如我們在講稿中強調的,是來自處方深度的提升。也就是說,我們正在獲得更多開立醫師,並讓他們先試用這個藥。而且當他們累積到兩位、三位、四位、五位病患啟用時,你就會開始看到一種幾乎像是觸發式的轉變:他們開始優先使用 YUTREPIA。我認為產品特性本身已能說明一切,它正在重新定義前列環素治療所需的條件。你需要一種能直接作用於受損部位的療法。因此必須送達肺部。它必須將肺部不耐受性以及非目標效應降到最低,而印製(print)劑型確實能做到這點。

  • And then because tolerability and dosing are inextricably linked, it allows for higher dosing, which allows for better outcomes. So when you have that type of product profile and sites have their own, quote-unquote, critical mass of trialing the drug, it quickly then becomes the preferred therapy at centers. And that's what we're seeing. We're certainly driving all of the growth in the space currently. If you sort of aggregate our revenue and our competitor revenue over the quarter, the market grew about 5%, and we were responsible for all of that growth, which we're quite pleased about, and I think it speaks for itself about what the leading therapy is.

    此外,由於耐受性與劑量調整密不可分,它使得可以使用更高劑量,進而帶來更佳的治療結果。因此,當你擁有這樣的產品特性,且各中心對該藥的試用達到其所謂的「臨界規模」時,它很快就會成為中心的首選治療。這正是我們目前看到的情況。我們確實正在推動目前該領域的全部成長。如果你把我們與競品本季的營收加總來看,市場約成長 5%,而這些成長全部由我們貢獻;我們對此相當滿意,我也認為這本身就說明了哪一個是領先療法。

  • We still see equal scripting between PH and PH-ILD. The pull-through still remains around 85%, which is extraordinarily good. And the naive and transitions are, again, about 75% to 25% as it has been before. So it's a bit more of the little engine that could, doing all that it has from day one and sustaining that trajectory.

    我們仍看到 PH 與 PH-ILD 的處方開立量相當。拉動率(pull-through)仍維持在約 85%,這是非常出色的表現。而初治(naive)與轉換(transitions)的比例同樣約為 75% 對 25%,與先前一致。所以這有點像那台「小火車也能做到」的故事,從第一天起就做到這些,並持續維持這樣的軌跡。

  • And then, Rusty, maybe you could talk to sort of thinking around Hikma and if there's any read-through from that case.

    接著,Rusty,也許你可以談談對 Hikma 的看法,以及該案是否有任何可供參照之處。

  • Russell Schundler - General Counsel, Secretary

    Russell Schundler - General Counsel, Secretary

  • Sure. Thanks, Roger, and thanks for the question, Amy. So I think if you look at the Hikma case and look at the briefing and the oral argument, that case really is a case about what's necessary to show induced infringement. Obviously, that's what's an issue in our case with at least four of the six claims where the parties are contesting (inaudible) therapeutics patents. I think also if you look at some of the conducts that's an issue in the Hikma case. I think there are some clear parallels to the conduct that United Therapeutics has cited in our case.

    當然。謝謝你,Roger,也謝謝你的提問,Amy。我認為,如果你看 Hikma 案並檢視其書狀與口頭辯論,那個案件本質上是在討論要證明「誘導侵權」(induced infringement)需要哪些要件。顯然,這也是我們案件中的爭點,至少在六項主張中的四項,雙方正在爭執(聽不清)Therapeutics 的專利。另外,如果你看 Hikma 案中所涉及的一些行為。我認為其中有一些與 United Therapeutics 在我們案件中所引用的行為存在明顯相似之處。

  • So I think there are certainly some similarities now whether -- how Hikma is going to be decided, whether it's going to affect Judge Andrew's decision, whether it affects the timing of Judge Andrew's decision, I think that would be speculation on speculation and not an area we're going to get into. But I think at least based on what we know today. So certainly, there are some parallels between the cases, but it's really hard to comment beyond that.

    因此我認為確實存在一些相似性;但 Hikma 將如何裁決、是否會影響 Andrew 法官的判決、是否會影響 Andrew 法官作出判決的時間點,我認為那將是對推測再推測,我們不會在這方面多作評論。但我認為至少就我們目前所知。所以,兩案之間確實有一些相似之處,但要再往下評論就很難了。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Yeah. And I think I would add, look, we remain very confident in the arguments that we made in the case and are bullish on the outcome of the opinion when it's rendered. And I think if there's any read-through from Hikma, we also feel that potentially would go in our favor as well.

    是的。我想我會補充:我們對在本案中提出的論點仍然非常有信心,並對意見書出爐時的結果抱持樂觀。而且我認為,如果 Hikma 案有任何可供參照之處,我們也覺得那可能同樣會對我們有利。

  • Operator

    Operator

  • Ryan Deschner, Raymond James.

    Raymond James 的 Ryan Deschner。

  • Ryan Deschner - Analyst

    Ryan Deschner - Analyst

  • Thanks for the question and congrats on another really strong quarter. By my math, the YUTREPIA launch has now eclipsed the early launch trajectory for your competitor. In terms of net sales, what is the current split between prescribers in major centers and smaller community prescribers look like? And how has this been falling thus far for the launch? And then I have a follow-up. Thanks.

    謝謝回答問題,也恭喜再度交出非常強勁的一季。依我的計算,YUTREPIA 的上市表現如今已超越你們競品在早期上市階段的軌跡。就淨銷售額而言,目前大型中心與較小型社區開立醫師的占比大約如何?而在上市至今的過程中,這個分布是如何演變的?我還有一個追問。謝謝。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Yeah. We're fortunate to have Scott Moomaw, our Chief Commercial Officer on. So Scott, if you wouldn't mind responding to that question.

    好的。我們很幸運 Scott Moomaw(我們的商務長)也在線上。Scott,如果你不介意的話,請你回應這個問題。

  • Scott Moomaw - Chief Commercial Officer

    Scott Moomaw - Chief Commercial Officer

  • Yeah, thanks. So as you would expect and as we mentioned on earlier calls, the centers were jumping in early. They had those patients, they are prevalent and ready to go, and they continue to be a mainstay. Although I will say, we have centers that are coming on even still now, whether they would be late adopters or they're starting to see those patients back after six months and starting to see the results of YUTREPIA.

    是的,謝謝。如你所預期、也如我們在先前的電話會議中提到的,這些中心很早就開始採用。他們手上已有那些病患,屬於既有且已準備好開始治療的族群,而且他們仍然是主要支柱。不過我也要說,我們現在仍持續有中心加入,不論是較晚採用者,或是他們在六個月後開始看到那些病患回診,並開始看到 YUTREPIA 的結果。

  • Having said that, we are having more success in the community, whether that be physicians who have used a PH drug before or even some physicians who have -- who are ILD prescribers with the antifibrotics, but we are ready to try a prostacyclin. So the balance is definitely changing a bit more towards what we call the community, but the centers are still the largest cohort. And of course, they actually are still growing as well.

    話雖如此,我們在社區端也取得更多成功,不論是曾使用過 PH 藥物的醫師,或甚至一些—一些是 ILD 開立抗纖維化藥物的處方醫師,但他們已準備好嘗試前列環素類藥物。因此,整體平衡確實正稍微轉向我們所稱的社區端,但中心仍是最大的族群。當然,中心端其實也仍在成長。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Great. Thanks, Scott. I would just maybe add, again, it's an anecdotal, but one of the favorite story -- feedback stories that we continue to get is, again, the competitor product has been on the market for years ahead of us. And it counter detailed us quite strongly. So when we went to centers, people would -- some of the physicians would say, they felt that these drugs were sort of -- were more alike than not.

    很好。謝謝你,Scott。我可能再補充一下,這是軼事性的,但我們持續收到、也很喜歡的一個故事—回饋故事是:競品已比我們早多年上市。而且它對我們形成相當強的競爭壓力。所以當我們去到中心時,有些醫師會說,他們覺得這些藥物某種程度上—相似之處多於差異。

  • But then when we go back to them and they begin prescribing YUTREPIA, they come back with their own anecdote around that they're seeing a night-and-day difference, particularly around the cough and the ability to hydrate and drive outcomes. So it's those types of stories that resonate with me. And I think, again, it's very hard to beat a better product profile, and I think that's what YUTREPIA [ports]

    但當我們回去、他們開始開立 YUTREPIA 後,他們會帶著自己的軼事回饋說,他們看到天壤之別,特別是在咳嗽以及補水能力與帶動療效方面。所以這類故事對我很有共鳴。而且我認為,再次強調,很難打敗更好的產品特性,我想這正是 YUTREPIA[ports]

  • Operator

    Operator

  • Serge Belanger, Needham.

    Serge Belanger,Needham。

  • Serge Belanger - Analyst

    Serge Belanger - Analyst

  • Hi, good morning. Thanks for taking my questions. Roger, we're coming up on the one-year anniversary of FDA approval YUTREPIA. So you've been in the market for close to a year now. How large do you think the PH-ILD opportunity currently stands at? And how large do you think it could be?

    嗨,早安。謝謝回答我的問題。Roger,我們即將迎來 YUTREPIA 獲 FDA 核准的一週年。所以你們在市場上已接近一年。你認為目前 PH-ILD 的機會規模有多大?你覺得它可能成長到多大?

  • And then one question for Mike. I noticed you're now an income taxpayer of the company. Just curious if this is a one-off or you expect to continue being paying income taxes going forward and at what rate? Thanks.

    另外一個問題給 Mike。我注意到你們現在成為公司的所得稅納稅人。想請教這是一次性的,還是你們預期未來會持續繳納所得稅?稅率大概是多少?謝謝。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Thanks, Serge. I'll take the first question around PH-ILD. So if you aggregate just the inhaled [treprostinil] in market today in real dollars, it's about $2 billion. And that seems to be split somewhat evenly between PAH and PH-ILD at least for us. So clearly, the PH-ILD market is massively underpenetrated. I think we're driving awareness. I think our competitors driving awareness, so I think there's going to be a rising tide phenomenon for that.

    謝謝你,Serge。我先回答關於 PH-ILD 的第一個問題。如果把目前市場上吸入型 [treprostinil] 的實際美元銷售額加總起來,大約是 20 億美元。而且至少就我們而言,這看起來在 PAH 與 PH-ILD 之間大致各占一半。因此很明顯,PH-ILD 市場的滲透率仍然非常低。我認為我們正在提升認知。我也認為競爭對手也在提升認知,所以我認為這會出現「水漲船高」的現象。

  • Our belief is that's well in excess of $2 billion to $3 billion on its own in PH-ILD. And then don't forget with the oral prostacyclin, if you assign $1 billion in today revenue value, the oral market there is $2 billion in value. So there's another $3 billion. So just across PAH and PH-ILD, there's a potential -- and again, with clear line of sight without a lot of exaggeration or hyperbole to $6 billion in revenue. So a lot more runway here for us to continue to grow this franchise significantly.

    我們相信,單就 PH-ILD 而言,規模遠超過 20 億到 30 億美元。另外別忘了口服前列環素類藥物,如果你把目前的營收價值估為 10 億美元,那麼口服市場的價值是 20 億美元。所以那裡還有另外 30 億美元。因此,橫跨 PAH 與 PH-ILD,存在一個潛在—而且再次強調,在不需要太多誇大或渲染、且有清楚可見路徑的情況下,可達 60 億美元營收的機會。所以我們還有很長的跑道,能持續顯著擴大這個產品線的成長。

  • And certainly, as we begin to develop L606, which we're actively recruiting, we've had patients in screening already that's the next-gen molecule that can further open up access to these markets. So again, I'm very pleased with where we are today, but excited about where we're going to go tomorrow as well.

    當然,隨著我們開始開發 L606(我們正在積極招募),我們已經有病患進入篩檢流程;那是下一代分子,能進一步擴大進入這些市場的機會。所以再次強調,我對我們今天的進展非常滿意,也對我們明天將前往的方向感到興奮。

  • And maybe, Mike, I'll turn it over to you the tax question.

    另外,Mike,我把稅務問題交給你。

  • Michael Kaseta - Chief Financial Officer and Chief Operating Officer

    Michael Kaseta - Chief Financial Officer and Chief Operating Officer

  • Yeah. Thanks, Roger, and thanks for the question, Serge. As you saw, we did record income tax expense in Q1, as Roger has said in the prepared remarks, we're growing profitability. We're growing at a quick pace. We would expect to continue to show income tax expense as we move forward as we've been saying since launch, and we'll continue to say our goal is to obviously grow sales but also grow profitability and reinvest some of that profitability into the business. So the expectation is that we will have increasing net income and adjusted EBITDA as we move forward. And correspondingly, we'll have additional income tax expense.

    好的。謝謝你,Roger,也謝謝你的問題,Serge。如你所見,我們在第一季認列了所得稅費用;正如 Roger 在事先準備的發言中所說,我們的獲利能力正在提升。我們以很快的速度成長。我們預期未來會持續呈現所得稅費用,正如我們自上市以來一直在說的;我們也會持續強調,我們的目標顯然是成長銷售,同時提升獲利,並將部分獲利再投資於業務。因此,我們預期未來淨利與調整後 EBITDA 會持續增加。相應地,我們也會有更多的所得稅費用。

  • Operator

    Operator

  • Julian Harrison, BTIG.

    Julian Harrison,BTIG。

  • Julian Harrison - Analyst

    Julian Harrison - Analyst

  • Hi, let me -- congratulations on all the recent progress and thanks for taking the questions. Two for me. First, are you seeing any emerging trends among patients switching to YUTREPIA from other therapies. Has there been acceleration on that front at all? And what is the most common product you're seeing switching from at this point?

    嗨,讓我—恭喜你們近期的所有進展,也謝謝回答問題。我有兩個問題。第一,你們是否看到病患從其他療法轉換到 YUTREPIA 的任何新興趨勢?在這方面是否有任何加速?目前你們最常看到是從哪一個產品轉換過來?

  • And then second, thinking a little bit more about your $1 billion revenue by 2027 guidance that you announced earlier this year. Is there a chance you could achieve that on a run rate basis before 2027? Any thoughts there? Thanks.

    第二,進一步談談你們今年稍早公布的 2027 年達到 10 億美元營收的指引。你們是否有機會在 2027 年之前就以年化運行率(run rate)的基礎達成?有任何想法嗎?謝謝。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • So in terms of trends in switching, maybe I'll ask Rajeev to talk about that from his observations when he's been out in the field talking to docs. And then also maybe, Rajeev, if you could speak to the studies that we're doing to direct patients from other prostacyclins to YUTREPIA as well. And then, Mike, if you'll not answer the question on run rate. Your best question to answer for Julian, that you can when you get there. So Rajeev?

    關於轉換趨勢,也許我請 Rajeev 從他在外勤與醫師交流時的觀察來談談。另外 Rajeev,如果你也能談談我們正在進行的研究,如何把使用其他前列環素類藥物的病患導向 YUTREPIA。然後,Mike,如果你願意的話再回答運行率的問題。這是給 Julian 的最佳問題,你到時候能回答多少就回答多少。Rajeev?

  • Rajeev Saggar - Chief Medical Officer

    Rajeev Saggar - Chief Medical Officer

  • Thanks, Roger. And thanks, Julian, for the question. So I think what is clear is that -- and [you] asked to this before, I think the community and the centers like, I think we're experiencing an inhaled renaissance. And I think this is clearly being led by YUTREPIA's product profile. I think that Roger continues to highlight in this call, and that's really that the tolerability of our print formulation has led to the ability to dose higher.

    謝謝你,Roger。也謝謝你,Julian,提出問題。我認為很清楚的是—而且你之前也問過,我認為在社區端與中心端,我們正經歷一波吸入治療的復興。而我認為這顯然是由 YUTREPIA 的產品特性所帶動。我想 Roger 在這通電話會議中持續強調的一點是,我們乾粉(DPI)配方的耐受性,使得劑量能夠提高。

  • And we showed in our ASCENT cohort (inaudible) PH-ILD that as we go up every higher every 8 weeks, that has resulted in notable changes in exercise capacity for these patients to distances and changes that we have not seen in the past. And where this has gone is that practitioners in our opinion, when we speak to them, has realized that especially with this vast armamentarium that's now available in both Group 1 and now also in Group 3 that we're moving more towards making the patient not only clearly wanting to feel better, walk further, live longer. But we need to do that in a way that is extremely tolerable.

    我們在 ASCENT 隊列(聽不清)PH-ILD 中顯示,當我們每 8 週逐步上調到更高劑量時,病患的運動能力出現顯著變化,達到的距離與改善幅度是我們過去未曾見過的。而這帶來的結果是,依我們的看法,當我們與臨床醫師交流時,他們已意識到,特別是在第 1 群、以及現在也包括第 3 群都有如此龐大的治療武器庫可用之下,我們正更朝向讓病患不僅明確想要感覺更好、走得更遠、活得更久。但我們必須以極高耐受性的方式來達成。

  • The construct of using pumps and even oral prostacyclins, especially given their significant GI intolerability has allowed the market to take a look at YUTREPIA in a different perspective. In particular, what we're realizing is that the oral prostacyclins market has -- in those practitioners, we've seen a large switch over to YUTREPIA. And although the pharmacokinetics are different, I think, again, the fact that we can dose YUTREPIA 1.5 to threefold what has traditionally been used with inhaled treprostinil has really opened their eyes to the fact.

    使用幫浦、甚至口服前列環素類藥物的治療模式——尤其考量其顯著的腸胃道(GI)不耐受性——使市場得以從不同角度看待 YUTREPIA。特別是我們觀察到,在口服前列環素類藥物市場中,那些臨床醫師族群已出現大量轉換至 YUTREPIA 的情況。儘管藥物動力學不同,但我認為,再次強調,我們能將 YUTREPIA 的劑量提高到傳統吸入型 treprostinil 的 1.5 到 3 倍,確實讓他們意識到這一點。

  • And the argument can be made well is 4 times a day. And that's correct. But the advantage of inhaled is that it's directly being administered to the lungs. We can negate all the -- significantly negate many of the off-target systemic side effects that are notable with oral prostacyclins regardless of the dosing frequency of the prostacyclin.

    而且也可以提出一個論點:那就是一天 4 次。這是正確的。但吸入給藥的優勢在於它是直接投送到肺部。我們可以消除——或大幅降低——許多口服前列環素類藥物常見的非靶向全身性副作用,而這些副作用不論前列環素的給藥頻率如何都可能出現。

  • And finally, with the use of (inaudible) coming abroad, I think we're seeing a huge number of practitioners starting to say why are we putting patients on parenteral therapy and a pump, which obviously had its advantages historically. But now we can wean that pump down, transition that also to YUTREPIA. And I think we'll see some abstracts being presented at ATS highlighting the utility of YUTREPIA in combinatory [trepro] and (inaudible) And I think from a company's perspective, we realize this is where we need to continue to create the data and show physicians how to also do it from a trial perspective. We've now started recruiting into ASCENT Cohort B, which is patients that are inadequately responsive to either Tyvaso nebulizer or Tyvaso DPI and transitioning that to YUTREPIA.

    最後,隨著(聽不清)在海外推出,我認為我們看到大量臨床醫師開始提出疑問:為什麼要讓病人使用腸外給藥與幫浦治療?這在過去當然有其歷史上的優勢。但現在我們可以把幫浦逐步減量,並將治療轉換到 YUTREPIA。我想我們會在 ATS 看到一些摘要發表,強調 YUTREPIA 在合併 [trepro] 與(聽不清)治療中的效用。而從公司角度來看,我們也意識到這正是我們需要持續產出數據、並向醫師展示如何在試驗設計層面實際操作的方向。我們已開始招募 ASCENT B 組,對象是對 Tyvaso 霧化器或 Tyvaso DPI 反應不足的病人,並將其轉換至 YUTREPIA。

  • We're also planning in the very near future to initiate transitioning from oral (inaudible) to open-label YUTREPIA. I think that one, of course, we initiated doing that because of, again, what is happening in the community. And finally, just to re-highlight we need to provide how to actually transition from parenteral therapy on patients on [sotatercept] and how to transition off the pump directly to YUTREPIA. And that study, we hope to be initiating some time in 2026/2027.

    我們也計畫在近期啟動從口服(聽不清)轉換至開放標籤(open-label)YUTREPIA 的研究。當然,我們之所以啟動這項研究,再次是因為社群端正在發生的情況。最後,再次強調:我們需要提供指引,說明對於正在使用 [sotatercept] 的腸外治療病人,如何進行轉換,以及如何直接從幫浦轉換到 YUTREPIA。該研究我們希望能在 2026/2027 年間的某個時間點啟動。

  • So hopefully, that provides a detailed response to your question, Julian.

    Julian,希望這能對你的問題提供更詳細的回覆。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • And Mike, if you'll talk about the run rate.

    Mike,請你談談 run rate(營收運行速度)。

  • Michael Kaseta - Chief Financial Officer and Chief Operating Officer

    Michael Kaseta - Chief Financial Officer and Chief Operating Officer

  • Yeah. So just to take the step back and thanks for the question, Julian. Just looking back from Q3 to Q4 and Q4 to Q1, we showed from a revenue share an inhaled prostacyclin, we've gone from Q3 of a 10% market share to Q4 at about a little over 16%. And in Q1 of '26, we've grown that to almost 23%. All while the market grew in Q4 and Q1 each by 5%. And this is in spite of the supposed terrible weather in the winter months here in Q4 and Q1.

    好的。那我先退一步看整體,也謝謝你的提問,Julian。回顧從第三季到第四季、以及第四季到第一季,從吸入型前列環素的營收市占來看,我們已從第三季的 10% 市占提升到第四季約略超過 16%。而在 2026 年第一季,我們已成長到接近 23%。同時,整體市場在第四季與第一季各自成長了 5%。而這還是在據稱冬季第四季與第一季天氣非常糟的情況下達成的。

  • So I think what we've shown is nothing short of amazing in terms of that growth. We see continued growth as we move forward. As Roger talked about, the opportunities in both PAH and PH-ILD, we think, are massive. We have a tremendous amount of momentum. We have a best-in-class product. We have a best-in-class commercial organization and medical affairs organization. And we have nothing but confidence as we move forward here.

    所以我認為,就這樣的成長而言,我們的表現可說是非常驚人。我們預期未來仍會持續成長。如 Roger 所提到的,無論在 PAH 或 PH-ILD,我們認為機會都非常龐大。我們擁有非常強勁的動能。我們有同級最佳(best-in-class)的產品。我們有同級最佳的商業團隊與醫藥事務(medical affairs)團隊。因此,對於接下來的推進,我們充滿信心。

  • We're not going to talk about run rate as we get towards the back end of the year. Rogers talked about at least $1 billion in 2027, but we feel that we have a tremendous amount of momentum that we will continue to build on as we move through the rest of 2026.

    我們不會在接近年底時討論 run rate。Roger 提到 2027 年至少 10 億美元,但我們認為我們有非常強的動能,並將在 2026 年剩餘時間持續累積。

  • Operator

    Operator

  • Ben Burnett, Wells Fargo.

    Wells Fargo 的 Ben Burnett。

  • Benjamin Burnett - Analyst

    Benjamin Burnett - Analyst

  • Hi, good morning. I wanted to actually ask about L606 and sort of expectations for the Phase 3. Based off the Phase 2 or the open label, I think patients were able to get at kind of 229 micrograms. That's -- I guess that's the median. But what are your expectations for kind of the dose that's achievable in Phase 3?

    嗨,早安。我想問一下 L606,以及對第三期(Phase 3)的預期。根據第二期或開放標籤研究,我記得病人能達到大約 229 微克。那——我想那是中位數。那你們對第三期可達到的劑量水準有什麼預期?

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Hi, good morning, Ben. So thanks for the question. Again, over to Rajeev for that.

    嗨,早安,Ben。謝謝你的提問。這題再請 Rajeev 來回答。

  • Rajeev Saggar - Chief Medical Officer

    Rajeev Saggar - Chief Medical Officer

  • Yeah, Ben, thanks for the question. I think just to re-acclimate to the audience L606 is our [treprostinil] inhalation suspension that is delivered twice a day. And I think one of the things YUTREPIA cannot solved as the 4 times a day, and L606, we are confident is going to be able to achieve the result that will be robust. We're obviously studying this in the setting of PH-ILD, and we anticipate the first patient to imminently come through in the short time period.

    Ben,謝謝你的提問。我先讓聽眾重新熟悉一下:L606 是我們的 [treprostinil] 吸入懸浮液(inhalation suspension),採每日兩次給藥。我認為 YUTREPIA 無法解決的一點是一天 4 次給藥,而我們對 L606 有信心能達到強健(robust)的結果。我們顯然是在 PH-ILD 的情境下研究它,並預期第一位受試者將在短期內很快入組。

  • In the open-label study, I think what we highlighted was really our construct that if you can deliver this twice a day, you can also sustain pharmacokinetics of treprostinil not only during the day, but an equivalent amount at nighttime. So that when you do a 6-minute walk test, we anticipate that we will not see a notable difference between trough and peak. And I think that's very important because when the patient wakes up, they should feel as good as they did as the day before when they're walking around.

    在開放標籤研究中,我想我們強調的是我們的核心設計:如果能做到每日兩次給藥,就能維持 treprostinil 的藥物動力學,不僅在白天,夜間也能維持相當的暴露量。因此在進行 6 分鐘步行測試時,我們預期不會看到谷濃度(trough)與峰濃度(peak)之間有明顯差異。我認為這非常重要,因為病人早上醒來時,應該要感覺跟前一天走動時一樣好。

  • In terms of dosing, I think what we have learned with YUTREPIA is that we need to continue to provide customization to dosing to the patients. And to do that, we should be able to dose to maximum effect and dose that can tolerate and clinically need it. And there'll also be patients that also need maybe less amounts based on their own clinical response. So I think the jury is still out. I think what is clear is that the way that we've created our dose levels do allow for significant dose titratability to levels that we also have been achieved in our -- with YUTREPIA are to use comparable dose level effects.

    就劑量而言,我認為我們從 YUTREPIA 學到的是:我們需要持續為病人提供劑量客製化。而要做到這點,我們應能把劑量調到最大療效、以及病人可耐受且臨床上需要的劑量。同時也會有一些病人,基於其自身臨床反應,可能需要較低的劑量。所以我認為目前仍未有定論。但可以確定的是,我們所設計的劑量階梯,確實允許顯著的劑量可滴定性(titration),可達到我們在——以 YUTREPIA 已達成的、可產生相當劑量效果的水準。

  • Benjamin Burnett - Analyst

    Benjamin Burnett - Analyst

  • All right. Thank you, Rajeev.

    好的。謝謝你,Rajeev。

  • Operator

    Operator

  • Jason Gerberry, Bank of America.

    美國銀行(Bank of America)的 Jason Gerberry。

  • Unidentified Participant

    Unidentified Participant

  • Hi, this is Melanie on for Jason. Thanks for taking our question. Going back to the PH-ILD market opportunity. assuming no change to the market indication statement, can you talk about the challenges and opportunities with opening up that market opportunity? I know you talked about market penetration already, but how penetrated is that market currently with inhaled panel is there a hurdle market? Is the hurdle market education and free diagnosis? Thanks.

    嗨,我是 Melanie,代 Jason 發問。謝謝讓我們提問。回到 PH-ILD 的市場機會:假設適應症敘述(indication statement)不變,你們能談談在開拓該市場機會時的挑戰與機會嗎?我知道你們已談過市場滲透率,但目前 PH-ILD 市場使用吸入型(治療)的滲透程度如何?是否存在一個「門檻市場」(hurdle market)?這個門檻是市場教育與更早診斷嗎?謝謝。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Great. So Scott, maybe you could take the answer on kind of what our expectations are in PH-ILD and where we are today.

    太好了。那麼 Scott,也許你可以回答一下我們對 PH-ILD 的預期大概是什麼,以及我們目前的進展到哪裡。

  • Scott Moomaw - Chief Commercial Officer

    Scott Moomaw - Chief Commercial Officer

  • Yeah, sure. Thanks. So I think we've said that we started with PH-ILD being a smaller percentage of the patients as we -- they are just a little bit of a slower burn in that market, but we're now to the point where it's pretty balanced in terms of 50-50. So you can see already that PH-ILD has increased.

    好的,當然。謝謝。我想我們之前有提到,一開始 PH-ILD 佔患者的比例比較小,因為——在那個市場的推進速度稍微慢一些,但我們現在已經到了大致平衡的狀態,大概是 50-50。所以你已經可以看到 PH-ILD 的占比提高了。

  • I think -- with that said, the market is still 60,000 patients and there is a lot of headroom here for this to continue to grow. I think as Roger alluded to earlier, two companies in this space educating, working on awareness, diagnosis and treatment is going to rise the tide for sure.

    我想——話雖如此,市場仍然有 60,000 名患者,而且這裡還有很大的成長空間,可以持續擴大。我想如 Roger 先前提到的,這個領域有兩家公司在做教育、提升認知、推動診斷與治療,肯定會帶動整體市場水位上升。

  • One of the reasons we're doing the sales force expansion here over the next couple of months is because we want to penetrate further out into the community market where these are physicians, community pulmonologists to prescribe who see ILD patients but they don't spend a lot of time thinking about it at any time thinking about whether those patients have PH. They'll give them antifibrotics and then they'll do the best that they can.

    我們在接下來幾個月進行銷售團隊擴編的原因之一,是因為我們希望更深入滲透到社區市場;那裡的醫師、社區肺科醫師會開立處方,他們會看 ILD 病人,但平常不太會花時間去思考這些病人是否合併 PH。他們會給予抗纖維化藥物,然後盡其所能處理。

  • But having said that, I think that there's an opportunity to get out there to talk to these physicians because many of these patients are out there in the community, and they haven't made it to a center yet. So you go to that doctor, you make them aware, you get them thinking about PH-ILD, you explained to them what a terrible disease this is and what the mortality looks like for it and then ask them to look for it. And if they're either treat it, or diagnosis, I should say, diagnose it and then either treat it or send it into a center. But I think that's where the opportunity lies as those patients that are out there are kind of in the jungle, and that's why, as I mentioned earlier, we're expanding the sales force. So we think there's a great deal of opportunity [out] there.

    但即便如此,我認為我們有機會走出去與這些醫師溝通,因為很多病人其實就在社區端,還沒有到醫學中心。所以你去拜訪那位醫師,讓他們提高警覺、開始思考 PH-ILD,向他們說明這是一種多麼嚴重的疾病、其死亡率大概是什麼樣子,然後請他們去留意篩查。如果他們——要嘛治療,或者我應該說,先做出診斷,然後要嘛治療、要嘛轉介到中心。但我認為機會就在於:那些在外面的病人有點像是在叢林裡,而這也是為什麼如我先前提到的,我們要擴編銷售團隊。所以我們認為外面有非常大的機會。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Yeah. And the other thing I would add, there's recent registry type data that's coming out that's showing that 50% to 75% of these patients actually have a PH component to their ILD. So really, as Scott said, it's driving awareness and getting them to refer to a cath lab to do a definitive right heart cath so that they can then have the authorization to get scripted for a drug that can help them. So -- and a lot of it is driving the disease awareness, driving the PH incidents within the ILD population. So there's sort of an expectation that it's actually there rather than not there.

    是的。另外我想補充的是,近期有一些登錄(registry)類型的資料顯示,這些患者中其實有 50% 到 75% 的 ILD 合併 PH 成分。所以確實如 Scott 所說,關鍵在於提升認知,並讓他們轉介到導管室做明確的右心導管檢查(right heart cath),這樣之後才能取得核准,開立能幫助他們的藥物處方。所以——很大一部分是在推動疾病認知、推動 ILD 人群中 PH 的發生率被辨識出來。因此某種程度上,大家會預期它其實是存在的,而不是不存在。

  • And then finally, either they're going to learn to treat or they're going to learn to refer and what the best referral network is for them. So that's what we're doing. And that's, as Scott said, one of the reasons we scaled the sales force significantly.

    最後,他們要嘛會學會治療,要嘛會學會轉介,以及對他們而言最佳的轉診網絡是什麼。所以這就是我們正在做的事。而且如 Scott 所說,這也是我們大幅擴編銷售團隊的原因之一。

  • Operator

    Operator

  • Gaurav Maini, LifeSci Capital.

    Gaurav Maini,LifeSci Capital。

  • Phillip Eckert - Analyst

    Phillip Eckert - Analyst

  • Yeah, good morning. Phillip Eckert jumping in for Gaurav today. Thanks for taking the question. I guess any more color you can give on the potential expansion opportunity for YUTREPIA in PH-COPD. Of course, this is a pretty wide-open indication, but any color here on how the team is thinking about this would be helpful.

    是的,早安。今天由 Phillip Eckert 代替 Gaurav 發言。謝謝讓我提問。我想請問,關於 YUTREPIA 在 PH-COPD 的潛在擴張機會,你們是否能提供更多細節。當然,這是一個相當開放的適應症,但若能分享團隊目前如何思考這件事,會很有幫助。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Yes, I'll start. So we think there's a clear opportunity here. And I think part of what will drive the value of sort of capturing that opportunity is doing a study that is enriched, if you will, for success. So we're -- at ATS, for example, we're going to have steering committee meetings with the luminaires in the space to talk about kind of if we're going to study this disease, what is the best sample of patients to study, and I think if we get that right, we all know that treprostinil will improve the PH component of disease and that can -- that obviously would benefit the outcome of patients with PH=COPD.

    好的,我先開始。我們認為這裡有明確的機會。而我想,推動捕捉這個機會價值的一部分,在於做一項可以說是「富集」成功機率的研究。所以我們——例如在 ATS 期間,會與該領域的權威專家召開指導委員會會議,討論如果要研究這個疾病,最適合納入研究的患者樣本是什麼;我想只要這點做對了,我們都知道 treprostinil 會改善疾病中的 PH 成分,而這——顯然會有助於改善 PH-COPD 患者的結局。

  • So I think that's where we're going to focus our time and attention on is making sure we get the inclusion, exclusion criteria, right. We've been -- we'll do a protocol that's with all our experience that we think will be enriched for success, and then we'll take it to goal. So that's kind of where we are with that program. So it's -- it won't get going until '27 at best. So I think more to come on that, but I appreciate the question. It's a massive opportunity in excess of $4 billion or more on its own.

    所以我想我們會把時間與注意力放在確保納入與排除標準設定正確。我們一直——會基於我們所有的經驗制定一份我們認為能提高成功機率的試驗方案,然後把它推進到目標。所以這就是我們在該計畫上的現況。因此——最理想也要到 2027 年才可能啟動。所以我想後續還會有更多更新,但謝謝你的提問。這是一個龐大的機會,單獨就可能超過 40 億美元甚至更多。

  • Operator

    Operator

  • Thank you. This does conclude the question-and-answer session of today's program. I'd like to hand the program back to Dr. Roger Jeffs for any further remarks.

    謝謝。今天節目的問答環節到此結束。我想把節目交回給 Roger Jeffs 醫師,請他做進一步的結語。

  • Roger Jeffs - Chief Executive Officer, Director

    Roger Jeffs - Chief Executive Officer, Director

  • Yes. Thank you, operator, and thank you, everybody, for joining us. I think I'd just leave you with we're really excited about where the business is headed. I think we're going to focus on four key areas. One is the continued success in the launch of YUTREPIA in its growth, doing market support studies to cement our position for YUTREPIA, anchoring prostacyclin in the market, both for transitions from inhaled and oral, looking at synergies with sotatercept. We're also going to focus on L606 advancement and get that to goal as soon as we can. And then as we just answered the question around evolving broader indications, such as IPF, PPF, PH-COPD and Raynaud's, so that we can expand this business by multiples and not present. So again, thank you, everyone, for your time and attention today. We look forward to speaking to you at conferences in the coming future.

    好的。謝謝主持人,也謝謝各位今天參與。我想最後想留給大家的是:我們對公司業務的發展方向感到非常振奮。我想我們會聚焦四個關鍵領域。第一,是持續推動 YUTREPIA 上市的成功與成長,並進行市場支持性研究以鞏固我們在 YUTREPIA 的地位,將前列環素(prostacyclin)在市場中作為核心錨定,涵蓋從吸入與口服治療的轉換,同時尋找與 sotatercept 的協同效應。我們也會聚焦於推進 L606,並盡快達成目標。再者,如同我們剛才回答關於拓展更廣泛適應症的問題,例如 IPF、PPF、PH-COPD 與雷諾氏症(Raynaud's),以便讓這項業務以倍數擴張,而不僅僅是目前的規模。再次感謝各位今天撥冗與關注。我們期待在不久的將來於各項會議上與各位交流。

  • Operator

    Operator

  • Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.

    感謝各位女士、先生參與今天的會議。本節目到此結束。您現在可以掛線。祝各位有美好的一天。